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FORUM ORIGINAL RESEARCH COMMUNICATION
Neuronal Activity Controls the Antagonistic Balance Between
Peroxisome Proliferator-Activated Receptor-g Coactivator-1a
and Silencing Mediator of Retinoic Acid and Thyroid Hormone
Receptors in Regulating Antioxidant Defenses
Francesc X. Soriano, Fre´de´ric Le´veille´, Sofia Papadia, Karen F.S. Bell,
Clare Puddifoot, and Giles E. Hardingham
Abstract
Transcriptional coactivators and corepressors often have multiple targets and can have opposing actions on
transcription and downstream physiological events. The coactivator peroxisome proliferator-activated receptor-g
coactivator (PGC)-1a is under-expressed in Huntington’s disease and is a regulator of antioxidant defenses and
mitochondrial biogenesis. We show that in primary cortical neurons, expression of PGC-1a strongly promotes
resistance to excitotoxic and oxidative stress in a cell autonomous manner, whereas knockdown increases
sensitivity. In contrast, the transcriptional corepressor silencing mediator of retinoic acid and thyroid hormone
receptors (SMRT) specifically antagonizes PGC-1a-mediated antioxidant effects. The antagonistic balance be-
tween PGC-1a and SMRT is upset in favor of PGC-1a by synaptic activity. Synaptic activity triggers nuclear
export of SMRT reliant on multiple regions of the protein. Concommitantly, synaptic activity post-translationally
enhances the transactivating potential of PGC-1a in a p38-dependent manner, as well as upregulating cyclic-
AMP response element binding protein-dependent PGC-1a transcription. Activity-dependent targeting of PGC-
1a results in enhanced gene expression mediated by the thyroid hormone receptor, a prototypical transcription
factor coactivated by PGC-1a and repressed by SMRT. As a consequence of these events, SMRT is unable to
antagonize PGC-1a-mediated resistance to oxidative stress in synaptically active neurons. Thus, PGC-1a and
SMRT are antagonistic regulators of neuronal vulnerability to oxidative stress. Further, this coactivator–core-
pressor antagonism is regulated by the activity status of the cell, with implications for neuronal viability.
Antioxid. Redox Signal. 14, 1425–1436.
Introduction
Changes in gene transcription in response to externalsignals mediate the coordinated control of many adaptive
biological processes. These changes are mediated by DNA
sequence-specific transcription factors that bind to gene pro-
moters and regulate their transcription. In neurons, the reg-
ulation of gene transcription by synaptic activity is an integral
part of processes that regulate neuronal differentiation, de-
velopment, long-term plasticity, and defenses against excito-
toxic, apoptotic and oxidative insults (10, 12, 21, 24, 32). This
control is classically viewed to be exerted via the direct
modification of Ca2þ-responsive transcription factors that
bind Ca2þ-responsive promoter elements (48). However,
more recently it has become apparent that Ca2þ signals can
influence transcription by targeting a different class of pro-
teins: transcriptional coactivators and corepressors (4, 15,
28, 42).
Transcription factors do not exist in isolation: most signal-
dependent transcription factors require association with
broad-specificity coactivators to promote transcription
through the recruitment of chromatin remodeling complexes.
The transcriptional coactivator peroxisome proliferator-
activated receptor-g (PPARg) coactivator 1a (PGC-1a) controls
important physiological and metabolic processes in a diverse
array of tissues. These include glucose metabolism, energy
homeostasis, adaptive thermogenesis, and mitochondrial
biogenesis (11, 37). In neurons, PGC-1a regulates mitochon-
drial density, antioxidant defenses, and vulnerability to ex-
citotoxic insults (45, 47). Moreover, it is under-expressed in
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Huntington’s disease (HD) as a direct result of mutant Hun-
tingtin (mtHtt)-mediated repression, potentially contributing
to HD pathogenesis (6, 27, 49). PGC-1a mediates its effects
through the coactivation of a number of transcription factors,
such as nuclear respiratory factors 1 and 2, the myocyte en-
hancer factor 2 (MEF2) family, and nuclear receptors, in-
cluding PPARg, estrogen receptors (ER), thyroid hormone
receptor (TR), and the retinoic acid receptor (RAR) (37, 38).
This coactivation involves the recruitment of chromatin-
modifying complexes to the promoter, which may contain
histone acetyl transferases, methyltransferases, and nucleo-
some destabilizing enzymes (23).
As well as associating with coactivators when in an active
state, many signal-regulated transcription factors when in
their basal, uninduced state are not merely inactive but me-
diate active repression via the association of broad-specificity
corepressors. As such, transcription factor activity can be
influenced by the balance between coactivator and corepres-
sor activity. A key corepressor is silencing mediator of retinoic
acid and thyroid hormone receptors (SMRT) that interacts
with many signal-dependent transcription factors (19) and
mediates repression by recruiting further repressors such as
class I and II histone deacetylases (HDACs) (18, 19). SMRT
represses many transcription factors that are coactivated by
PGC-1a, including PPARg, ER, TR, RAR, and MEF2s (19, 35,
46, 50). This raises the possibility that SMRT may antagonize
some of the physiological processes mediated by PGC-1a.
Here we have studied how PGC-1a and SMRT control
cortical neuronal vulnerability to oxidative and excitotoxic
insults, and the influence of neuronal activity on these tran-
scriptional coregulators. We find that SMRT can block the
ability of PGC-1a to protect neurons against oxidative insults,
but cannot antagonize the antiexcitotoxic effect of PGC-1a
expression. Further, we find that neuronal activity, by acti-
vating PGC-1a and repressing SMRT function, upsets this
antagonistic balance in favor of the neuroprotective PGC-1a.
Materials and Methods
Neuronal cultures and stimulations
Cortical neurons from E21 Sprague Dawley rats were cul-
tured as described (2) except that the growth medium was
comprised of Neurobasal A medium þ B27 (Invitrogen), 1%
rat serum, and 1 mM glutamine. Experiments were performed
after a culturing period of 9–10 days during which cortical
neurons develop a rich network of processes, express func-
tional N-methyl d-aspartate (NMDA)-type and AMPA=
kainate-type glutamate receptors, and form synaptic contacts.
Stimulations were performed after transferring neurons into a
defined medium lacking trophic support ‘‘TMo’’ (33): 10%
MEM (Invitrogen), 90% Salt-Glucose-Glycine medium (1); Salt-
Glucose-Glycine: 114 mM NaCl, 0.219% NaHCO3, 5.292 mM
KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM HEPES, 1 mM Glycine,
30 mM Glucose, 0.5 mM sodium pyruvate, 0.1% Phenol Red;
osmolarity 325 mosm=l, hereafter TMo. Stimulations were ini-
tiated approximately 48 h after transfection. Bursts of action
potential firing were induced by treatment of neurons with
50mM bicuculline (BiC), and burst frequency was enhanced by
addition of 250mM 4-amino pyridine (14). 3,30,5-Triiodo-L-
thyronine (T3 hormone) was used at 50 nM. The p38 inhibitor
SB203580 (Calbiochem) at 5 mM was added 30 min before the
stimulation.
Western blotting and antibodies
Total cell lysates were boiled at 1008C for 5 min in
1.5sample buffer (1.5 M Tris pH 6.8; Glycerol 15%; SDS 3%;
b-mercaptoethanol 7.5%; bromophenol blue 0.0375%). Gel
electrophoresis and Western blotting were performed using
Xcell Surelock system (Invitrogen) using precast gradient gels
(4%–20%) according to the manufacturer’s instructions. The
gels were blotted onto PVDF membranes, which were then
blocked for 1 h at room temperature with 5% (w=v) nonfat
dried milk in TBS with 0.1% Tween 20. The membranes were
then incubated at 48C overnight with the primary antibodies
diluted in blocking solution: anti-PGC-1a (1:1000; a gift from
Marc Montminy, The Salk Institue), enhanced green fluores-
cent protein (eGFP; 1:1000; Invitrogen), and Akt (1:500; Cell
Signalling). For observation of Western blots, HRP-based
secondary antibodies were used followed by chemilumines-
cent detection on Kodak X-Omat film.
RNA isolation, reverse transcriptase-polymerase chain
reaction, and quantitative polymerase chain reaction
RNA was isolated using the Qiagen RNeasy isolation re-
agents (including the optional DNAse treatment) following
passage of the cells through a QiaShredder column. For
quantitative polymerase chain reaction (qPCR), cDNA was
synthesized from 1 to 3 mg RNA using the Stratascript qPCR
cDNA Synthesis kit (Stratagene, Amsterdam, Netherlands)
according to the manufacturer’s instructions. Briefly, the re-
quired amount of RNA (up to 3 mg) was diluted in RNase-
free water (up to 7 mL final volume) and mixed on ice with
1cDNA Synthesis master mix (10 mL), random primers:
oligo-dT primers 3:1 (total 2mL–200 ng) and either 1mL
RT=RNase block enzyme mixture (for RT reactions) or 1mL
water (for No RT control reactions). Reaction mixtures were
mixed and spun down and incubated for 2 min at 258C,
40 min at 428C, and 5 min at 958C. cDNA was stored at
208C. Dilutions of this cDNA were subsequently used for
real-time PCR (cDNA equivalent to 6 ng of initial RNA per
15 mL qPCR reaction except GAPDH; cDNA equivalent to
2 ng initial RNA per 15mL reaction for GAPDH). qPCR was
performed in an Mx3000P QPCR System (Stratagene) using
Brilliant SYBR Green QPCR Master Mix (Stratagene) ac-
cording to the manufacturer’s instructions. Briefly, the re-
quired amount of template was mixed on ice with 1Brilliant
SYBR Green Master Mix, the required concentration of for-
ward and reverse primers, 30 nM ROX passive reference dye,
and water to the required reaction volume. Technical repli-
cates as well as no template and no RT negative controls were
included and at least three biological replicates were studied
in each case. The sequence of the primers used are as follows:
Rat PGC-1a–F: 50-gaatgcagcgctcttagc-30, -R: 50-gct ttt gct gtt
gac aaa tg-30 rat GAPDH–F: 50-aga agg ctg ggg ctc acc-30
200 nM, -R: 50-agt tgg tgg tgc agg atg c-30 100 nM; 18s rRNA–
F: 50-gtg gag cga ttt gtc tgg tt-30, -R: 50-caa gct tat gac ccg cac
tt-30. The cycling programme was 10 min at 958C; 40 cycles of
30 s at 958C, 40 s at 608C with detection of fluorescence and
30 s at 728C; 1 cycle (for dissociation curve) of 1 min at 958C
and 30 s at 558C with a ramp up to 30 s at 958C (ramp rate:
0.28C=s) with continuous detection of fluorescence on the
558C–958C ramp. The data were analyzed using the MxPro
QPCR analysis software (Stratagene). Expression of the gene
of interest was normalized to GAPDH, a commonly used
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control, which is invariant against a second control [18s
rRNA (32)].
Plasmids
TR-Luc and GFP-SMRTa full length was a gift from
Martin Privalsky [UC Davis (17)]. For construction of GFP-
SMRT1233–2472, GFP-SMRT1523–2472, GFP-SMRT1–590, GFP-
SMRT1–1854, and GFP-SMRT1–1018, GFP-SMRTa was
digested with HindIII and EcoRI, HindIII and PmlI, SfiI and
XhoI, BsrU36I and XhoI, and PmlI and XhoI, respectively,
and then the ends were blunted using DNA Polymerase I
Large (Klenow) Fragment (Promega) enzyme and religated.
For the construction of GFP-SMRTD1018–1523 GFP-SMRTa
was digested with PmlI to remove the nucleotides codifying
for the region 1018–1523 and religated. For the construction
of GFP-SMRT1–1523 an MluI restriction site was inserted by
directed mutagenesis and digested with MluI and XhoI
blunt ended and religated. GFP-SMRTD1609–1697 and GFP-
SMRTD1681–1694 was constructed by amplifying by PCR the
whole GFP-SMRTa plasmid except the nucleotides coding
for the region 1609–1697 and 1681–1694 by using the
primers forward 50-ata cgc gtg ggt atg gag gtg ggg tca aa-30
and reverse 50-taa cgc gtg ccg ctg gcc caa gag gca tt-30 and
forward 50-ata cgc gtc atg tca gca cgc tgg gcc at-30 and re-
verse 50-taa cgc gta att atg ccg ctg gcc caa gag-30, respec-
tively, which contain an MluI restriction site (adding to the
sequence two extra amino acids, Thr and Arg). The PCR
product was digested with MluI and religated. To clone the
repression domain 3 (RD3)-myc (SMRT1024–1526) this region
was amplified using the primers forward 50-acg aat tca tgc
cag tgc ctc ctg ccg aga aag ag-30 and 50-cgc tct aga tca cag atc
ttc ttc aga aat aag ttt ttg ttc tgg cag gtg act ggt gaa ggg-30,
PCR product was cloned in XbaI=EcoRI sites of pEF1=
V5-His A expression vector (Invitrogen). pTK-RL was form
Promega. PGC-1a-luc and PGC-1aDCRE-luc were a gift from
A. Fukamizu (University of Tsukuba (7); GAL4-PGC-1a,
pcDNA-PGC-1a, and pcDNA-PGC-1a-3A were a gift from
P. Puigserver (Dana Farber Cancer Institute); pcDNA-PGC-
1a-3D was from Addgene (8). PGC-1a and PGC-1a-3D was
subcloned in the pEF=V5-His A vector (invitrogen) by ex-
cising the cDNA form the pcDNA vector with EcoRI and
AgeI digestion and blunting it to clone it in the EcoRV site of
the pEF=V5-His A vector.
Immunofluorescence
Immunofluorescence was performed as described (26). Pic-
tures of GFP-SMRT construct-expressing neurons were taken
on a CCD camera driven by Openlab software, and the sub-
cellular distribution scored. Distribution was scored as nuclear
if localization was exclusively nuclear, whereas significant
observable GFP immunofluorescence in the cytoplasm counted
as a cell that exhibited SMRT export. Anti-GFP antibody (In-
vitrogen) was used (1:600) and observed using biotinylated
secondary antibody=cy3-conjugated streptavidin. Nuclei were
counter-stained with DAPI. For each treatment,*150–200 cells
were analyzed within 3–5 independent experiments.
Transfections and gene expression analysis
Neurons were transfected using Lipofectamine 2000 (Pro-
mega) and stimulated 24–48 h after transfection. For gene
expression analysis cells were then incubated overnight or for
8 h and luciferase activity read out. Luciferase assays were
performed using the Dual Glo assay kit (Promega) with
Firefly luciferase-based reporter gene activity normalized to
the Renilla control (pTK-RL plasmid) in all cases. Mean
SEM of 3–6 experiments is shown. Where used, siRNA
(PGC-1a or Dharmacon’s control nontargeting siRNA #2
siRNA) was at 100 nM. siRNA sequences used were as fol-
lows: (i) 50-caa uga aug cag cgg ucu u-30; (ii) 50-gaa caa gac uau
uga gcg a-30.
Following the fate of transfected cells
This was performed essentially as described (43). Briefly,
pictures of GFP-expressing neurons were taken using a Leica
AF6000 LX imaging system, with a DFC350 FX digital camera.
Neurons were then treated with 100 mM H202 or 30 mM
NMDA and images of the same cells were taken 24 h
after H2O2 exposure. Cell death was assessed by counting
the number of surviving GFP-positive neurons pre- and
post-exposure to H202. In the vast majority of cases, death was
easily spotted as an absence of a healthy GFP-expressing cell
where one once was. In place of the cell, there was in most
cases (>90%) evidence of death in the form of fragmented
neurites, fluorescent cell debris, and an apoptotic nucleus.
This confirmed that the cells were genuinely dying as op-
posed to a more unlikely scenario such as peroxide-induced
quenching of eGFP fluorescence in a sub-population of neu-
rons. This is also underlined by the fact that death measured
by this technique is blocked by caspase inhibitors (32). For
each plasmid=condition, the fate of *150–200 neurons was
monitored over 3–5 independent experiments.
Results
PGC-1a is strongly protective against
oxidative and excitotoxic insults
To assess the extent of neuroprotection afforded by PGC-1a
in primary cortical neurons, we transfected neurons with a
vector encoding PGC-1a driven by a constitutively active
promoter, plus an eGFP vector to identify transfected neu-
rons. The fate of these neurons was monitored both before and
after the application of an oxidative insult (100mM H2O2).
Consistent with the known ability of PGC-1a to boost anti-
oxidant defenses in other systems, expression of PGC-1a
rendered cortical neurons essentially resistant to this oxida-
tive insult (Fig. 1A, B). Further, this protective effect appeared
to be cell autonomous: no significant resistance to oxidative
insults was observed in untransfected neurons even when in
proximity to the PGC-1a-expressing neurons (Fig. 1C). We
also investigated the effect of siRNA directed against PGC-1a
on neuronal viability. Validation of PGC-1a-directed siRNA
was hampered by the absence of a PGC-1a antibody that
detects endogenous neuronal PGC-1a by immunohisto-
chemistry at this developmental stage (in our hands), and the
fact that siRNA transfection efficiency is too low to analyze
knock-down of endogenous protein by Western blot. Instead,
we overexpressed Flag-tagged PGC-1a and analyzed the ef-
fectiveness of the siRNA in preventing PGC-1a expression,
finding one that worked particularly well (siRNA #2, Fig. 1D
inset). We confirmed the efficacy of this siRNA by showing
that it completely blocked the protective effect of PGC-1a
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overexpression when cotransfected with the PGC-1a expres-
sion vector (data not shown). This siRNA, when transfected
into neurons, had the effect of increasing the amount of death
observed after H2O2 exposure (Fig. 1D), indicating that en-
dogenous PGC-1a is a regulator of cortical antioxidant de-
fenses, in agreement with previous studies on neuroblastoma
cells and striatal neural progenitor cells (45).
PGC-1a has also been reported to confer protection
against excitotoxic insults such as kainate-induced seizure,
oxygen-glucose deprivation, and mtHtt-induced death (6,
25, 31, 45). While excitotoxic insults undoubtedly have an
oxidative component, other routes to neuronal death are also
triggered that are not associated with oxidative stress (13).
We therefore wanted to know whether PGC-1a protected
against an excitotoxic insult in our system as effectively as it
did for oxidative insults. We exposed control- and PGC-1a-
expressing cortical neurons to an excitotoxic dose of NMDA
and once more saw near complete resistance to this insult
(Fig. 1E).
SMRT specifically represses
the antioxidant boosting effects of PGC-1a
As a coactivator, PGC-1a promotes the transactivating
potential of many transcription factors, including nuclear re-
ceptors and MEF2s. These and other transcription factors as-
sociate with PGC-1a-containing coactivator complexes when
active but also are capable of mediating active transcriptional
repression when associated with corepressor complexes in
their inactive state. Taking the example of nuclear hormone
receptors, their coactivator- and corepressor-associated forms
exist in an equilibrium that is pushed in favor of the active
FIG. 1. Expression of peroxisome proliferator-activated receptor-c coactivator 1a (PGC-1a) protects neurons against
neurotoxic insults. (A) Expression of PGC-1a in cortical neurons protects against H2O2-induced neuronal death. The neurons
were transfected with control (globin) or PGC-1a vector, plus an enhanced green fluorescent protein (GFP) expression vector
to monitor cell fate (see Materials and Methods). Twenty-four hours post-transfection neurons were treated where indicated
with H2O2 (100mM) and cell fate monitored after a further 24 h. Scale bar¼ 30mm. (B) Quantification of data shown in A.
Death indicated by loss of GFP-positive cells. Transfected neurons were identified after 24 h and their fate was monitored at
24 h. 100–160 neurons were studied per treatment across five independent experiments. *p< 0.05, Bonferonni two-tailed
paired t-test in this and subsequent figures unless stated. Mean SEM shown here and throughout all figures. (C) Cell
autonomous effect of PGC-1a expression on H2O2-induced neuronal death. Survival=death of neurons within a 150mm radius
of PGC-1a-expressing neurons was analyzed by assessing nuclear morphology of DAPI-stained fixed cells. As can be seen in
A, healthy neurons have large nuclei with diffuse DAPI staining. Apoptotic nuclei are characterized by pyknotic brightly
stained clumps of condensed chromatin. (D) Knock-down of PGC-1a makes cortical neurons more sensitive to H2O2-induced
neuronal death. Survival=death of neurons transfected with a control siRNA or siRNA directed against PGC-1a were treated
as in A 48 h after transfection *p< 0.05 (n¼ 4). An example of a Western validating the siRNA efficacy is also shown. (E)
Expression of PGC-1a protects cortical neurons against N-methyl d-aspartate (NMDA)-induced cell death. Neurons were
transfected as in A and treated with NMDA (30mM) for 1 h. After 24 h they were fixed and death assessed. *p< 0.05 (n¼ 5).
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state by presence of cognate ligand but can also be influenced
by the level of corepressors or coactivators available (41).
SMRT is a transcriptional corepressor that exerts its effects
by binding target transcription factors and recruiting other
repressor molecules such as HDACs. It shares several targets
with PGC-1a, including nuclear receptors and MEF2s, raising
the possibility that SMRT could exert opposite effects to PGC-
1a with respect to vulnerability of neurons to oxidative and
excitotoxic insults. We therefore investigated the effect of
SMRT expression on vulnerability to these trauma. We found
that expression of SMRT alone did not affect basal viability
(data not shown), nor did it increase neuronal vulnerability to
H2O2-induced oxidative death (Fig. 2A). However, SMRT
completely blocked the protective antioxidant effects of PGC-
1a expression (Fig. 2A). We next looked at the effect of SMRT
expression on the vulnerability of neurons to NMDA receptor
(NMDAR)-dependent excitotoxic death. In this case, SMRT
expression alone did not exacerbate cell death but neither did
it antagonize the protective effect of PGC-1a expression (Fig.
2B). Thus, SMRT antagonizes the antioxidant effects of PGC-
1a but not the antiexcitotoxic effects. This indicates that these
two PGC-1a-driven neuroprotective effects are mechanisti-
cally different, and that SMRT specifically antagonizes those
PGC-1a-mediated events that ultimately boost resistance to
oxidative insults.
Synaptic NMDAR activity boosts PGC-1a transcription
in vitro and in vitro
Synaptic activity, acting in part by triggering synaptic
NMDAR-dependent Ca2þ transients, is able to control the ac-
tivity, expression, and subcellular localization of several
broad specificity transcriptional coactivators and corepres-
sors. We next investigated the influence of synaptic activity on
PGC-1a and SMRT function and its implications for the an-
tagonistic effect of SMRT on PGC-1a-dependent antioxidative
effects.
Membrane depolarization, triggering Ca2þ entry, is known
to upregulate the transcription of PGC-1a (29), indicating that
synaptic activity is likely to do the same. We used an estab-
lished method of network disinhibition to enhance synaptic
activity, by applying the gamma-aminobutyric acid A recep-
tor antagonist BiC. This treatment results in synchronized
bursts of action potentials that are associated with intracellular
FIG. 2. Expression of silencing mediator
of retinoic acid and thyroid hormone re-
ceptors (SMRT) blocks specifically the
protective effect of PGC-1a on H2O2-
mediated cell death but not the NMDA-
mediated cell death. Cortical neurons
were transfected with a eGFP-encoding
vector plus the indicated vectors (encoding
PGC-1a and=or SMRT), with the control
vector used wherever either vector was not
transfected. Twenty-four hours after
transfection, pictures were taken of trans-
fected neurons before they were treated
with 100mM H2O2 (A) or 30 mM NMDA
(B), and cell fate monitored after a further
24 h. *p< 0.05 (n¼ 5 for A and B). ns, not
significant.
FIG. 3. Synaptic activity
induces PGC-1a gene ex-
pression in a cyclic-AMP
response element binding
protein (CREB)-dependent
manner. (A) Synaptic activity
was induced in cortical cul-
tures by bicuculline (BiC,
50mM) plus 4-amino pyridine
(250 mM; labeled BiC, here and
through the study) for 24 h
followed by RNA extraction
and quantitative RT polymer-
ase chain reaction analysis of
PGC-1a mRNA expression
(normalized to GAPDH). A
Western of PGC-1a (Akt is
used as loading control) is also shown. *p< 0.05 (n¼ 4). (B) In vivo N-methyl d-aspartate receptor blockade reduces PGC-1a
mRNA levels. P6 mice were subjected to intraperitoneal injection of saline (Con) or MK-801 (for 12 h) followed by RNA
extraction and quantitative RT polymerase chain reaction analysis of PGC-1a mRNA expression (normalized to GAPDH,
*p< 0.05 [n¼ 4]). (C) The promoter of PGC-1a is activated in a CREB-dependent manner by synaptic activity. A PGC-1a-luc
reporter of the wild-type promoter or with the CREB binding site mutated (PGC-1aDCREB-luc) was transfected in cortical
neurons, after 24 h the culture was stimulated with BiC for 24 h and luciferase activity was read (normalized to renilla here
and in all luciferase assays; see Materials and Methods). *p< 0.05 (n¼ 3).
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Ca2þ transients dependent on influx through NMDARs, as
well as release from internal stores and some influx through
voltage-gated channels (14). The Kþ channel antagonist 4-
aminopyridine (4-AP) was coapplied with BiC to enhance
burst frequency (14) (hereafter BiC=4-AP). BiC=4-AP treat-
ment resulted in the upregulation of PGC-1a mRNA and
protein expression (Fig. 3A). In vivo, suppression of physio-
logical NMDAR activity by treatment with MK-801 caused a
downregulation of PGC-1a expression (Fig. 3B), indicating
that PGC-1a is regulated by activity both in vitro and in vivo.
PGC-1a is a known target of the transcription factor cyclic-
AMP response element binding protein (CREB) that is itself
known to be strongly activated by synaptic NMDAR activity.
Synaptic activity induced a luciferase based reporter of the
PGC-1a promoter that was impaired if the CRE site was
mutated (Fig. 3C), strongly indicating that activity-dependent
induction of PGC-1a is via CREB.
Synaptic activity boosts PGC-1a activity
post-translationally via p38.
As well as being subject to transcriptional regulation, PGC-
1a has also been reported to be subject to post-translational
control. Cytokine stimulation of muscle cells has been shown
to induce PGC-1a’s intrinsic activity via its p38-dependent
phosphorylation (36) that prevents the binding of the re-
pressor protein p160MBP (8).
Since synaptic activity can trigger p38 activity (44) we
considered the possibility that PGC-1a could be subject to
activity-dependent post-translational control. To study the
post-translational regulation of PGC-1a directly we tested
the ability of PGC-1a, tethered to the promoter by means of
fusion to a GAL4 DNA binding domain, to confer activity-
dependent inducibility on a luciferase-based reporter contain-
ing multiple GAL4 binding sites. Expression of GAL4-PGC-1a
resulted in an 11-fold activation of the reporter compared to
expression of the GAL4 domain alone (Fig. 4A), consistent
with a significant degree of basal activity. However, trigger-
ing synaptic activity with BiC=4-AP resulted in a further
fivefold enhancement of PGC-1a-dependent gene expression,
indicating that PGC-1a’s intrinsic activity is enhanced by
neuronal activity (Fig. 4B). To investigate this further we
looked at the role of p38 in this activation process. We found
that pretreatment with the p38 inhibitor SB202580 strongly
inhibited the potentiating effect of synaptic activity on GAL-
PGC-1a-mediated reporter activity (Fig. 4B).
PGC-1a promotes the activation of nuclear receptors, in-
cluding the TR (37, 38). TR-mediated gene expression is
suppressed by SMRT, and so represents an example of one of
several transcription factors that could integrate the opposing
actions of PGC-1a and SMRT. We recently found that synaptic
activity can super-induce T3 hormone activation of the TR.
This was associated with the activity-dependent nuclear ex-
port of SMRT and the dissociation of SMRT from TR promoter
FIG. 4. Synaptic activity enhances the
transcriptional activity of PGC-1a in a
p38-dependent manner. (A) Neurons
were transfected with an UASGAL4-luc
reporter vector plus vectors encoding
either GAL4 DNA binding domain
alone or GAL4-PGC-1a expression
vector. Twenty-four hours post-
transfection luciferase activity was
measured. *p< 0.05 (n¼ 4). (B) Synap-
tic activity-mediated increase in PGC-
1a transcriptional activity via p38
signaling. Cortical neurons were trans-
fected with an UASGAL4-luc reporter
vector plus pTK-Renilla plus GAL4-
PGC-1a expression vector. Twenty-four
hours post-transfection luciferase neu-
rons were stimulated with BiC in the
absence or presence of the p38 inhibitor
SB203580 added at 5mM 30 min before
the stimulation, and after 8 h luciferase
activity was measured. *p< 0.05
(n¼ 4). (C) Synaptic activity-dependent
enhancement T3 hormone-responsive-
ness is p38 dependent. Neurons were
transfected with an thyroid hormone
receptor (TR)-luc reporter vector, plus
pTK-Renilla. Twenty-four hours post-
transfection, neurons were stimulated
with BiC in the absence or presence of T3 hormone (50 nM). Where used, the p38 inhibitor SB203580 was added at 5mM
30 min before the stimulation. After 16 h stimulation, luciferase activity was measured. *p< 0.05 (n¼ 4). #p< 0.05 compared to
equivalent non-T3 treated condition. (D) Mutation of the three p38 phosphorylation sites on PGC-1a abolish the synaptic
activity-mediated enhancement of T3-responsiveness. Neurons were transfected with a TR-luc reporter vector plus PGC-1a or
PGC-1a3A in which amino acids T262, S265, and T298 (sites phosphorylated by p38) have been mutated to Alanine. Twenty-
four hours post-transfection neurons were stimulated (where indicated) with 50 nM T3BiC for 24 h. *p< 0.05 (n¼ 4).
#p< 0.05 compared to equivalent non-BiC treated condition.
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elements (28). Our observation that PGC-1a can also be reg-
ulated by synaptic activity raised the possibility that activity-
dependent activation of PGC-1a via p38 may contribute to this
process. We first assessed the role of p38 in the induction of
T3-responsiveness by synaptic activity. In agreement with our
previous study, synaptic activity did not induce TR reporter
activity in the absence of hormone (Fig. 4C). However, in the
presence of T3, coincident BiC=4-AP-induced synaptic activ-
ity potentiated the response (Fig. 4C). Moreover, inhibition of
p38 reversed this potentiation (Fig. 4C). Note that the effect
of p38 inhibition was restricted to the potentiating effect of
synaptic activity: neither basal TR reporter activity nor ac-
tivity induced by T3 alone was inhibited by p38 inhibition.
This rules out a nonspecific effect of p38 inhibition on overall
ability of the TR to promote transcription.
We wanted to know if PGC-1a is a target of the p38 pathway
in boosting TR-mediated gene expression. p38-dependent ac-
tivation of PGC-1a is mediated by phosphorylation on three
different sites (36). Mutation of these residues to alanine
abolishes p38-inducibility of PGC-1a-mediated processes
without reducing basal PGC-1a activity. We investigated the
effect of this mutant (PGC-1a3A) on the activity-mediated, p38-
dependent boosting of TR-mediated gene expression. Com-
pared to expressing wild-type PGC-1a, expression of PGC-1a-
3A had the effect of specifically inhibiting the potentiating
effect of activity on TR-mediated gene expression (Fig. 4D).
Basal T3-induced, TR-mediated gene expression (in the ab-
sence of synaptic stimulation) was not affected (Fig. 4D).
We also confirmed that PGC-1a3A has similar basal activity
to wild-type PGC-1a with regard to its ability to protect
against H2O2-induced death (data not shown). The effect of
PGC-1a3A in specifically interfering with activity-mediated,
p38-dependent boosting of TR-mediated gene expression
suggests that phosphorylation of these sites may contribute to
the p38-mediated effects observed.
SMRT’s RD3 domain confers
nuclear localization in neurons
We previously reported that synaptic activity promotes
the nuclear export of SMRT and dissociation of SMRT from
target transcription factors including the TR (28). Activity-
dependent redistribution of SMRT to the cytoplasm is ob-
served in the presence of the protein synthesis inhibitor
cycloheximide (data not shown), confirming that the pre-
existing SMRT is exported (rather than, e.g., newly synthe-
sized SMRT being retained in the cytoplasm). Thus, neuronal
synaptic activity can inactivate SMRT as well as activate PGC-
1a. To investigate this nuclear export further we created de-
letion mutants of SMRT spanning its entire 2472 amino acids.
We first investigated the region(s) of SMRT that confer
nuclear localization under normal conditions in neurons. A
C-terminal portion of SMRT (SMRT1223–2472) was nuclear-
localized, but this was lost in the SMRT1523–2472 portion,
implicating the 1223–1523 region (Fig. 5B, C). Consistent
with this, an internal deletion of region 1018–1523
(SMRTD(1018–1523)), which encompasses SMRT’s RD3 domain,
caused a reduction (but not complete loss) in nuclear locali-
zation (Fig. 5C). In contrast, deletion of a region spanning
SMRT’s RD4 domain (SMRTD(1523–1854)) did not affect nuclear
localization. Further, a portion of SMRT containing the RD3
region (SMRT1025–1523) is nuclear when expressed (Fig. 5C), as
has been reported in Hela cells (50). Thus, the RD3 domain is
an important determinant of SMRT nuclear localization in
neurons.
However, the fact that SMRTD(1018–1523) retained some nu-
clear localization (Fig. 5C) is suggestive of further sequences
conferring nuclear localization in the N-terminal 1018 amino
acids. Indeed, the N-terminal portion of SMRT (SMRT1–1018)
was also strongly nuclear when expressed, although a smaller
region of SMRT (SMRT1–590) was not, appearing to be dis-
tributed evenly throughout the nucleoplasm (Fig. 5C). Col-
lectively these data indicate that the RD3 region is important
for conferring SMRT nuclear localization, but that the N-
terminal region can also localize to the nucleus independent of
this domain.
SMRT N- and C-terminal sequences
can mediate activity-dependent nuclear export
Study of the BiC=4-AP-induced export (Fig. 5D, E) revealed
that SMRT1–1854 undergoes export as effectively as full-length
SMRT but that SMRT1–1523 is exported slightly (but signifi-
cantly) less well, implicating the region between 1523 and
1854 in contributing to nuclear export (Fig. 5E). Deletion of a
smaller piece of this region (SMRTD1609–1697) also showed a
similar significant reduction in activity-dependent export
(Fig. 5F). Further examination of this region revealed a po-
tential nuclear export site (NES) (20) with sequence
LRGLSPRESSLA, which was deleted (SMRTD1681–1694), once
again showing a small but significant reduction in activity-
dependent export (Fig. 5F).
Surprisingly, however, further C-terminal deletion beyond
position 1523 (creating SMRT1–1018) restored activity-depen-
dent export to normal levels (Fig. 5E), suggesting that the
1018–1523 region of SMRT (containing the RD3 domain) acts
as a partial break on nuclear export. This portion of SMRT
(SMRT1025–1523) does not undergo export in response to syn-
aptic activity, remaining in the nucleus (Fig. 5G, H). Since both
N-terminal SMRT1–1018 and C-terminal SMRT1233–2507 un-
dergo normal activity-dependent export (Fig. 5E), we con-
clude that no single domain is likely to be critical for this
process, although the putative NES region may play a par-
tially nonredundant role.
Synaptic activity renders SMRT unable to suppress
PGC-1a-mediated antioxidative effects
We observed that coexpression of SMRT resulted in the
antioxidant effects of PGC-1a expression being inhibited (Fig.
2A). However, our findings that synaptic activity both induces
the activity of PGC-1a as well as triggering nuclear export of
SMRT (Figs. 3–5) suggests that the capacity of SMRT to an-
tagonize PGC-1a effects will be reduced. We found that in
BiC=4-AP-stimulated neurons, death induced by 100mM H2O2
was lower than in inactive neurons (compare Figs. 6A and 2A),
which is in agreement with our recent observations that syn-
aptic activity can boost intrinsic antioxidant defenses (13, 32).
Nevertheless, expression of PGC-1a in active neurons resulted
in further protection from H2O2-induced death (Fig. 6A).
Importantly, PGC-1a-mediated protection against oxida-
tive insults was still observed in SMRT-expressing neurons
(Fig. 6A). BiC=4-AP-induced synaptic activity rendered the
antagonizing effect of SMRT ineffective. This is consistent
with the effect of synaptic activity in enhancing PGC-1a
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FIG. 5. Several domains mediate the nuclear localization and activity-dependent nuclear export of SMRT. (A) Schematic
illustrating the SMRT constructs generated and used in this figure. (B) Examples of the cellular localization of three different SMRT
constructs. Arrowheads indicate transfected cells here and throughout the figure. (C) Several domains of SMRT confer nuclear
localization. Neurons were transfected with the indicated SMRT constructs. Forty-eight hours after transfection the cellular
localization of SMRT in >150 transfected neurons per construct was analyzed. *p< 0.05 (n¼ 4–6). (D) Synaptic activity induces
nuclear export of SMRT. Example of the cellular localization of SMRT in neurons transfected with GFP-SMRT and stimulated for
8 h with BiC or left unstimulated. (E) Several domains mediate the nuclear export of SMRT by synaptic activity. The indicated
GFP-SMRT constructs were transfected into neurons. Forty-eight hours after transfection the neurons were stimulated with BiC for
8 h and the cellular localization of SMRT was analyzed. *p< 0.05 (n¼ 5–6). (F) Analysis of activity-dependent export of SMRT
lacking a region containing a putative NES. *p< 0.05 (n¼ 4). (G) Analysis of the (lack of) activity-dependent export in a region of
SMRT corresponding to its repression domain 3 domain. *p< 0.05 (n¼ 3). (H) Example pictures from G. (For interpretation of the
references to color in this figure legend, the reader is referred to the web version of this article at www.liebertonline.com=ars).
FIG. 6. SMRT nuclear export or consti-
tutively active PGC-1a prevent SMRT-
mediated blockade of PGC-1a mediated
protection to H2O2 mediated cell death.
(A) Cortical neurons were transfected with
the indicated vectors and after 24 h were
stimulated with BiC for further 24 h. After
this time the neurons were then treated with
H2O2 (100mM) for a further 24 h, after which
cell death was assessed. *p< 0.05 (n¼ 5). (B)
Neurons expressing the indicated constructs
were treated with H2O2 (100 mM) for 24 h
after which cell death was assessed. In the
PGC-1a3D vector the amino acids T262, S265
and T298 have been mutated to Aspartic acid
to mimic phosphorylated residues. *p< 0.05
(n¼ 4).
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activity and suppressing SMRT activity. As to which of these
is most important, it is possible that both contribute. Un-
fortunately, because the activity-dependent export of SMRT is
mediated by multiple domains it was not possible to create a
nonexportable mutant of SMRT that could be tested for its
ability to antagonize PGC-1a-mediated effects in synaptically
active neurons. As such, the importance of SMRT export can
be predicted but is difficult to test experimentally.
To test whether PGC-1a phosphorylation could counteract
the suppressive effects of SMRT, we expressed a mutant form
of PGC-1a (PGC-1a3D) in which the three p38 phosphoryla-
tion sites have been mutated from serine=threonine to as-
partate to mimic the p38-phosphorylated form of PGC-1a (8).
The effect of this mutation is to render PGC-1a resistant to
p160MBP-mediated repression and thus enhance its basal ac-
tivity (8). We found that expression of PGC-1a3D in neurons
offered protection even when coexpressed with SMRT (Fig.
6B). The fact that SMRT could not completely suppress the
effects of PGC-1a3D indicates that phosphorylation on these
residues may be a contributing factor in regulating the an-
tagonistic balance between SMRT and PGC-1a with regard to
controlling antioxidant defenses.
Discussion
We have shown here that the transcriptional coactivator
PGC-1a is positively regulated by neuronal activity in vitro
and in vivo at the transcriptional level and at the post-
translational level in vitro. We have also demonstrated
that SMRT is able to antagonize the antioxidative, but
not antiexcitotoxic effects of PGC-1a. However, this antago-
nism is itself controlled=repressed by neuronal activity, po-
tentially through a combination of the aforementioned
enhancement of PGC-1a activity, plus activity-dependent
SMRT export.
PGC-1a directs neuroprotective gene expression
and its under-expression may contribute
to neurodegenerative diseases
As a transcriptional coactivator, PGC-1a controls the ac-
tivity of many transcription factors and acts as a master reg-
ulator of several important physiological processes in
neurons. PGC-1a-deficient mice exhibit lowered expression of
certain antioxidant genes in the brain, including Sod1, Sod2,
and catalase (45). Further, they show increased loss of dopa-
minergic neurons in response to treatment with MPTP
(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, which is me-
tabolized to the mitochondrial toxin MPPþ in dopaminergic
neurons). PGC-1a-deficient mice also show heightened levels
of hippocampal neuronal loss in a kainate seizure model of
excitotoxic cell death (45) and suffer from spontaneous striatal
lesions (22). Conversely, overexpression of PGC-1a in neuro-
blastoma cells and also striatal progenitor cells protects
against oxidative insults (45). PGC-1a also promotes protec-
tion in models of ischemia (5, 25). Overexpression of PGC-1a
boosts mitochondrial density in cortical neurons, leading to
increased ATP levels (47). Thus, as a regulator of mitochon-
drial function and antioxidant defenses, PGC-1a is neuro-
protective against a variety of insults.
It is possible that different (potentially overlapping) subsets
of PGC-1a regulated genes are responsible for protection
against different types of insult. For example, protection
against a purely oxidative insult may rely heavily on the
upregulation of antioxidant genes, whereas PGC-1a-mediated
resistance to excitotoxic insults may rely more on enhanced
mitochondrial function and energy production. Indeed, the
fact that SMRT can antagonize the antioxidative effects of
PGC-1a expression but not the antiexcitotoxic effects indicates
that different genes may be responsible for these two types of
neuroprotection.
Not only is PGC-1a neuroprotective against oxidative and
excitotoxic insults, but there is evidence that perturbation in
PGC-1a expression is a contributor to neurodegenerative
disease, particularly HD. mtHtt interferes with CREB-
dependent PGC-1a expression, leading to mitochondrial
dysfunction and metabolic defects (6, 49). PGC-1a expression
is lower in the striata of human HD patients, but not in the
cerebellum or hippocampus, consistent with the brain region-
specific effects of HD. As a further exacerbating factor, the
striatum appears to particularly vulnerable to loss of PGC-1a
expression above other brain regions (22). Overexpression of
PGC-1a protects both cortical and striatal neurons from
mtHtt- and 3-NPA-induced cell death, whereas lentiviral
transduction of PGC-1a reduces striatal loss in a mouse model
of the disease (6, 31, 47, 49). As well as being implicated in HD,
a recent study hints at involvement in Alzheimer’s disease
(39) where PGC-1a is reported to promote nonamyloidogenic
Amyloid Precursor Protein processing. Further, PGC-1a ex-
pression is lowered in human Alzheimer’s disease patients as
a function of dementia (39).
Dynamic control of PGC-1a by neuronal activity
Expression of PGC-1a in the brain is controlled by CREB (6,
31, 45) and boosted by synaptic NMDAR activity [this study
and ref. (31)]. In contrast, activation of extrasynaptic NMDAR
activity, which inhibits CREB activity (16) can suppress PGC-
1a expression in mtHtt-expressing neurons (31). The activity-
dependent nature of the PGC-1a gene suggests that PGC-1a
levels will mirror the activity history of the neuron and could
represent a way by which the elevated metabolic and anti-
oxidative demands placed on a neuron by high levels of
electrical activity could be met. Moreover, our study indicates
that PGC-1a activity can be regulated by post-transcriptional
mechanisms. Studies in myoblasts revealed that PGC-1a
contains a negative regulatory domain that recruits p160MBP,
resulting in lowered transactivation function (8). This associ-
ation is disrupted by p38-mediated phosphorylation (8) re-
presenting a potential point of rapid post-translational
control. We have shown here that p38 activity also boosts
PGC-1a activity in neurons and that a mutant nonpho-
sphorylatable form of PGC-1a inhibits p38-dependent en-
hancement of gene expression mediated by the TR, a nuclear
receptor coactivated PGC-1a. Moreover, the antioxidative ef-
fects of a phospho-mimetic mutant of PGC-1a is resistant to
suppression by SMRT, consistent with its higher transacti-
vating potential (although an alternative explanation is that
phosphorylation renders PGC-1a refractory to SMRT repres-
sion). As discussed below, the physiological effects of PGC-1a
are also subject to indirect activity-dependent regulation via
the nuclear export of the corepressor SMRT.
However, that p38-mediated phosphorylation of over-
expressed PGC-1a is not essential for protection by insults in
the absence of SMRT coexpression. Overexpression of a mutant
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nonphosphorylatable form of PGC-1a confers resistance to
both oxidative and excitotoxic insults (data not shown). Thus,
any requirement for PGC-1a phosphorylation may be in cases
where SMRT expression is significant, or PGC-1a levels are
low.
Antagonism of PGC-1a’s antioxidative effects
by SMRT is inhibited by synaptic activity
It remains unclear exactly which transcription factors are
responsible for PGC-1a-mediated protection against oxidative
insults, and it is likely that several are involved in coordi-
nating a general elevation in ROS-metabolizing capacity. The
fact that SMRT is able to antagonize the antioxidative effects
of PGC-1a suggests that key transcription factor mediators
include those that are targets for both these coregulators. Such
factors include (but are not restricted to) PPARg, ER, TR, RAR,
and MEF2s (19, 35, 46, 50). All the aforementioned tran-
scription factors have been reported to promote neuropro-
tective gene expression and=or resistance to oxidative insults
(3, 9, 30, 34, 40).
One can envisage a scenario whereby the balance of PGC-
1a coactivator versus SMRT corepressor activity influences the
activity of one or more of these factors, which in turn controls
the ROS metabolizing capacity of the neuron. As mentioned
above, the fact that SMRT cannot antagonize the ability of
PGC-1a to protect against an excitotoxic insult raises the
possibility that a different subset of PGC-1a-coactivated
transcription factors is involved in protection against ex-
citotoxic insults, than those involved in mediating the anti-
oxidative effects of PGC-1a (perhaps one or more key factors
mediating the antiexcitotoxic effects are not a target for
SMRT).
The finding that neuronal activity renders SMRT unable to
antagonize the antioxidative effects of PGC-1a could con-
ceivably be due to either activity-dependent SMRT export or
activity-dependent PGC-1a activation. The fact that the
phospho-mimetic PGC-1a3D is refractory to SMRT-repression
suggests that phosphorylation is sufficient in the context of
overexpression at least. Although this may be sufficient in
cases of strong activity or high PGC-1a expression, SMRT
export may also contribute in cases of modest levels of activity
or low PGC-1a expression. Neuronal activity, acting partly via
nuclear Ca2þ-dependent CaM kinase IV signaling, causes
SMRT export, which is associated with disruption of SMRT
interaction with its target transcription factors such as TR and
RAR, and sensitization of these factors to activation by their
cognate hormone (28). Blockade of nuclear Ca2þ signaling
inhibits activity-dependent enhancement of neuronal re-
sponsiveness to TR and RAR activation by their cognate
hormone (28). However, although nuclear Ca2þ signaling,
causing SMRT export, can be important in activity-dependent
potentiation of hormone-responsiveness, activation of PGC-
1a by p38 may also contribute, as outlined above.
Analysis of the regions of SMRT responsible for nuclear
localization and activity-dependent nuclear export in this
study have revealed that multiple domains are likely to be
responsible in both cases. Nuclear localization of SMRT is
disrupted in a mutant lacking the RD3 domain, which is the
region of SMRT that interacts with Class IIa HDACs, which
include HDAC4 and 5 (19). It is not currently clear whether
this region contains a bone fide nuclear localization signal
(NLS) or whether SMRT is localized to the nucleus through
association with nuclear factors such as Class IIa HDACs. Of
note, class IIa HDACs also undergo activity-dependent export
that occurs in advance of SMRT export (28) and so while
SMRT is clearly not being dragged out of the nucleus by class
IIa HDACs, their export may leave SMRT more sensitive to
export (28). Analysis of the effect of nonexportable mutants of
HDAC4 and HDAC5 on SMRT export (underway in the
laboratory) will elucidate the interdependency of SMRT and
Class IIa HDAC export by synaptic activity. The direct in-
vestigation of activity-dependent redistribution of multiple
deletion and truncation mutants of SMRT in this study indi-
cates that more than one domain must be responsible, since
nonoverlapping N- and C-terminal regions of SMRT exhibit
activity-dependent export (Fig. 5). Once again, we cannot
currently distinguish between autonomous export and ‘‘piggy
back export’’ via these domains, or through association with
other factors, particularly given the many factors with which
SMRT interacts.
Concluding Remarks
It is clear that the influence of activity-dependent Ca2þ
signaling extends beyond the direct regulation of Ca2þ-
responsive transcription factors. By influencing the function
of broad specificity coactivators and corepressors, activity-
dependent signals have the capacity to influence broad pro-
grams of gene expression, including genes controlled by
transcription factors that are not classically Ca2þ-responsive.
In demonstrating that neuronal activity can regulate the ability
of PGC-1a to protect neurons against oxidative insults, we
have increased our understanding of how endogenous signals
control the product of this important disease-associated gene.
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